In Re: Akebia Therapeutics v.

981 F.3d 32
Court of Appeals for the First Circuit·Decided November 20, 2020·No. 19-1929P·Published·Cited by 2 cases

Opinion

United States Court of Appeals For the First Circuit

No. 19-1929 IN RE: AKEBIA THERAPEUTICS, INC., Petitioner.

PETITION FOR WRIT OF MANDAMUS TO THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. Indira Talwani, U.S. District Judge]

Before

Thompson, Barron,

Circuit Judges.*

Michael L. Fitzgerald, with whom R. Daniel O'Connor, Patrick Welsh, Scott Grannemann, and Ropes & Gray LLP were on brief, for petitioner.

November 20, 2020

* Judge Torruella heard oral argument in this matter and participated in the semble, but he did not participate in the issuance of the panel's opinion in this case. The remaining two panelists therefore issued the opinion pursuant to 28 U.S.C. § 46(d).

THOMPSON, Circuit Judge. This petition for a writ of mandamus asks us to consider whether the district court properly determined an award of restitution to a corporate victim of a securities fraud conspiracy. The United States government, on behalf of Akebia Therapeutics, Inc., a biopharmaceutical company, sought reimbursement of $312,899.22 pursuant to the Mandatory Victims Restitution Act (MVRA). The requested reimbursement was for fees Akebia paid to attorneys it hired for assistance and advice while Akebia responded to requests for information during the government's investigation of suspected insider trading activities and provided evidence during the government's prosecution in United States v. Chan, et al., D. Mass. No. 16-cr- 10268. The district court awarded Akebia approximately half of the attorney's fees for which it had sought reimbursement. Dissatisfied, Akebia filed a petition for a writ of mandamus in this court pursuant to the Crime Victims' Rights Act (CVRA), 18 U.S.C. § 3771(d)(3), requesting a vacatur of the district court's restitution order and a reconsideration of some of the categories the district court did not allow.

For the reasons we explain below, we affirm.1

1Akebia, the government, and the defendants in the underlying case agreed to waive the usual 72-hour deadline we have under 18 U.S.C. § 3771(d)(3) to decide whether to grant the petition for a writ of mandamus. This Court acknowledged the waiver in its order entered on October 3, 2019 and clarified on October 28, 2019. See United States v. Aguirre-González, 597 F.3d 46, 55 (1st Cir. 2010)

BACKGROUND

In July 2018, a jury convicted Akebia's former Director of Biostatistics of conspiracy to commit securities fraud as well as three separate counts of securities fraud, convictions which we uphold today in a separately released opinion.2 During the sentencing phase of the prosecution, the government included a request for restitution on Akebia's behalf. Ropes & Gray LLP submitted a letter in support of Akebia's request for restitution, explaining Akebia had spent a lot of money to assist the government with the investigation and prosecution and made efforts to minimize its expenses by using its own employees as well as contract attorney firms for as much of the required document production requested by the government as possible. The letter asserted Akebia's expenses were reasonable, necessary, and foreseeable.

The defendants, Schultz Chan and Songjiang Wang, objected to the request and, after a hearing, the district court issued an initial order, separating the categories of expenses

(acknowledging the precatory rather than mandatory nature of the 72-hour timeframe provided in 18 U.S.C. § 3771(d)(3)). In those same orders, this Court denied the motion to consolidate this petition with the appeals from the underlying criminal convictions in United States v. Chan, et al., Nos. 18-2232, 18-2233, 19-1910, 19-1911, instead promising to coordinate the cases as best as possible. Our opinion in Chan issued today as well.

2 The same jury convicted the biostatistician's friend, who had been the leader of a statistical programming group at a different biopharmaceutical company, of one conspiracy count and two counts of securities fraud.

Akebia requested for reimbursement into two buckets: Either reimbursable or excluded as not necessary and foreseeable expenses. The district court deemed the following categories of expenses reimbursable as a foreseeable result of the defendants' conduct:

• "[C]osts of compiling and producing documents in response to government requests for those documents in connection with the criminal investigation";

• "[C]osts incurred in connection with Akebia employees'

preparation for interviews by the government prosecutors";

• "[C]osts incurred by Akebia as part of the restitution proceedings."

The district court also declared a few categories to be outside the scope of the MVRA and therefore not reimbursable:

• Fees and costs for outside counsel and summer associates to attend criminal proceedings • Fees related to a Freedom of Information Act request • Fees for a background check for a potential employee • Fees for insurance coverage analysis • Costs for public relations • Advice about state privacy laws • Office supplies • Fees for paralegals, clerks, summer associates, associates, partners, and litigation support analysts to read the indictment and other filings and prepare reports on same • Bills for taxis for attorneys working late on tasks other than document production and preparation of employees for interviews with the government.

The district court ordered the government to resubmit Akebia's request in accordance with the parameters the court had set forth.

The government resubmitted Akebia's request but objected to the district court's declaration that Akebia's outside

counsel's fees and costs for observing the trial proceedings fell outside the scope of the MVRA. Ropes & Gray LLP also again submitted a letter on Akebia's behalf, explaining the resubmission of the request for reimbursement included expenses only for the categories the district court had deemed reimbursable and asking the district court to reconsider its decision to exclude fees for outside counsel's attendance at the criminal proceedings.

On August 22, 2019, the district court issued a Memorandum and Order, awarding Akebia approximately half of the restitution requested ($170,476.36) and doubling down on its conclusion that the fees for the hours outside counsel spent watching and reporting on the criminal proceedings were neither reasonable nor foreseeable under the MVRA. The district court closely reviewed Akebia's request for restitution, discussing it category by category and explaining her reasoning as she went. She ultimately approved the following:

• 117.25 hours of non-attorney time to physically compile and produce documents requested by the government.

• 158.5 hours of attorney time - a close call but she concluded the government met its burden to show this time was necessary.

• Hours for Akebia employees to be prepped for interviews with government prosecutors because this time was deemed necessary.

• Transportation costs for attorneys to get to court to watch trial proceedings.

• 20% of the requested attorney time spent on seeking restitution because the full amount requested was deemed unreasonable.

• Attorney and non-attorney time allowed to be paid at the lowest number provided for each individual or position's hourly-rate range.

The district court denied the following requests:

• Expenses incurred before June 8, 2016 because Akebia had no contact with the DOJ before then.

• Certain entries for attorney and non-attorney time deemed insufficiently explained.

• Hours for attorney and non-attorney time preparing witnesses for trial because this was the purview of the government prosecutors, not private counsel.

• Attorney hours claimed to attend and report on the trial proceedings because these were neither necessary nor foreseeable expenses and were deemed a luxury.

• 80% of the requested attorney time spent on seeking restitution.

Akebia, unhappy with the restitution award amount, hopes we will decide the district court erred, and "require defendants to reimburse [it] for its necessary expenses."

DISCUSSION

Free access — add to your briefcase to read the full text and ask questions with AI

In Re: Akebia Therapeutics v., 981 F.3d 32 (1st Cir. 2020).

981 F.3d 32 (In Re: Akebia Therapeutics v.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Cardozo
68 F.4th 725 (First Circuit, 2023)
United States v. John Afriyie
27 F.4th 161 (Second Circuit, 2022)